Not a single study
Story checked
T-DXd significantly extends progression-free survival in HER2-mutant NSCLC (opens in a new tab)
news-medical.net · 2026-09-15
Short answer
Not a single studyNo clear answer.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
T-DXd significantly extends progression-free survival in HER2-mutant NSCLC
news-medical.net · 2026-09-15
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
This story isn't reporting one study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Open claim evidenceSearch result
No single source study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Source layer
The paper behind the story
The source record for this check.
The research anchor for the report.
- Also referencedpresented as the new finding
Phase 3 DESTINY-Lung04 trial shows first-line trastuzumab deruxtecan
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedFirst-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to primary results from the Phase 3 DESTINY-Lung04 trial.View evidenceHide evidence
As statedsignificantly improved progression-free survival
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 6Not checkedThe article says DESTINY-Lung04 was the first global Phase 3 trial to show a statistically significant and clinically meaningful progression-free survival benefit for first-line single-agent T-DXd over standard-of-care pembrolizumab plus platinum doublet chemotherapy.View evidenceHide evidence
As statedmedian progression-free survival 14.3 months with T-DXd versus 8.3 months with pembrolizumab plus chemotherapy; HR 0.63; 95% CI 0.50-0.79; P<0.0001
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 6Not checkedThe trial enrolled treatment-naive patients with unresectable locally advanced or metastatic NSCLC harboring HER2 exon 19 or exon 20 mutations, randomizing 454 patients 1:1 to T-DXd 5.4 mg/kg every three weeks or pembrolizumab plus platinum chemotherapy and pemetrexed.View evidenceHide evidence
As stated454 patients randomized 1:1
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 6Not checkedT-DXd also produced a higher objective response rate than pembrolizumab plus chemotherapy, and a longer median duration of response.View evidenceHide evidence
As statedobjective response rate 70.0% versus 44.5%; median duration of response 13.4 months versus 9.7 months
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 6Not checkedMedian overall survival was 29.3 months with T-DXd and 33.1 months with pembrolizumab plus chemotherapy, but investigators noted that subsequent therapies were imbalanced and confounded interpretation of the overall survival results.View evidenceHide evidence
As stated29.3 months versus 33.1 months
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 6Not checkedThe safety profile of T-DXd was described as generally consistent with its known profile, though adjudicated drug-related interstitial lung disease/pneumonitis occurred more often with T-DXd than with pembrolizumab plus chemotherapy.View evidenceHide evidence
As statedinterstitial lung disease/pneumonitis in 20.8% vs 2.3%; grade 3 or higher drug-related adverse events 34.1% vs 33.6%
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
Crossref, Europe PMC, PubMed · 15 candidate papers
DESTINY-Breast09: Trastuzumab Deruxtecan Plus Pertuzumab Sets New First-Line Benchmark in HER2-Positive Metastatic Breast Cancer
Default Digital Object Group · 2025 · Crossref
Antibody-Drug Conjugates in Non-small Cell Lung Cancer.
2026 · Europe PMC
Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study
Future Oncology · 2024 · Crossref
HER2 Alterations in Squamous Cell Lung Cancer: Biology, Therapeutic Landscape, and Emerging Precision Approaches.
2026 · Europe PMC
Trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer: a plain language summary of the DESTINY-Lung02 study
Future Oncology · 2026 · Europe PMC, Crossref
And 10 more candidates considered.